Trial Profile
A Phase I Study to Evaluate the Intravenous Pharmacokinetics and the Absolute Bioavailability of SRT2104 Given as a 250mg Oral Suspension in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs SRT 2104 (Primary) ; SRT 2104
- Indications Chronic obstructive pulmonary disease; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Sirtris
- 05 Aug 2011 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 15 Jul 2009 New trial record